Endometrial Cancer

Pembrolizumab plus lenvatinib improved outcomes compared with chemotherapy for women with advanced endometrial cancer, according to topline data released by the agents’ manufacturers.

Recreational physical activity appeared associated with improved survival outcomes among women with endometrial cancer, according to study results published in Journal of Clinical Oncology.

Uterine microbial diversity appeared higher among Black women diagnosed with endometrial cancer compared with their white counterparts, according to study results.

Consumption of caffeinated coffee does not appear to increase risk for various cancer types, according to a review article published in The New England Journal of Medicine.

Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.

Avelumab induced promising activity among women with mismatch repair-deficient endometrial cancer regardless of PD-L1 status, according to results of a prospective phase 2 trial published in Journal of Clinical Oncology.

The FDA, in conjunction with decisions by regulatory agencies in Australia and Canada, granted accelerated approval to pembrolizumab in combination with lenvatinib for the treatment of certain women with advanced endometrial carcinoma, according to a press release from the agency.

September is Gynecologic Cancer Awareness Month, an awareness campaign launched by the Foundation for Women’s Cancer.

Chemoradiotherapy significantly improved OS and failure-free survival compared with pelvic radiotherapy alone among women with high-risk endometrial cancer, according to results from the PORTEC-3 randomized phase 3 trial published in The Lancet Oncology.

AACR Frontiers in Cancer Prevention Research